LGALS9 and cancer: These results suggested that Gal-9 expression contributes to adaptive immune resistance that limits the immunogenicity of ICD and that, combined with anti-Gal-9, is a promising strategy for cancer treatment with immunogenic chemotherapy and radiotherapy that induce IFN-I expression in breast cancer.